US 12,391,650 B2
Catecholamine prodrugs for use in the treatment of Parkinson's disease
Morten Jørgensen, Valby (DK); Erhad Ascic, Valby (DK); Martin Juhl, Valby (DK); Klaus Gjervig Jensen, Valby (DK); Ask Püschl, Valby (DK); and Benny Bang-Andersen, Valby (DK)
Assigned to H. Lundbeck A/S, Valby (DK)
Appl. No. 17/606,303
Filed by H. Lundbeck A/S, Valby (DK)
PCT Filed May 19, 2020, PCT No. PCT/EP2020/063916
§ 371(c)(1), (2) Date Oct. 25, 2021,
PCT Pub. No. WO2020/234276, PCT Pub. Date Nov. 26, 2020.
Claims priority of application No. PA201900605 (DK), filed on May 21, 2019.
Prior Publication US 2022/0220077 A1, Jul. 14, 2022
Int. Cl. C07D 221/08 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07F 9/576 (2006.01); A61P 25/18 (2006.01); A61P 25/30 (2006.01)
CPC C07D 221/08 (2013.01) [C07F 9/5765 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A compound according to formula (Id)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein R1, R2 and R3 are according to a), b), or c) below:
a) R1 is substituent (i) below; and
R2 is selected from H, C1-C6 alkyl, benzyl and substituent (i) below;
and R3 is absent;
b) R1 is selected from H, C1-C6 alkyl, benzyl and substituent (i) below; and
R2 is substituent (i) below;
and R3 is absent;

OG Complex Work Unit Chemistry
wherein * indicates the attachment point,
or
c) R1 and R2 are both H and R3 is substituent (ii) below, N is positively charged,

OG Complex Work Unit Chemistry
and wherein * indicates the attachment point;
and wherein
R4 and R5 are each independently selected from H, C1-C6 alkyl, phenyl, benzyl, C3-C6 cycloalkyl and methyl substituted with C3-C6 cycloalkyl.